Dr. Weksler on Neoadjuvant and Adjuvant Therapy in NSCLC

Video

In Partnership With:

Benny Weksler, MD, FACS, chief, Division of Thoracic Surgery, professor, Surgery, University of Tennessee Health Science Center, Eastridge-Cole Endowed Professor of Thoracic Surgery, West Cancer Center, discusses the role of minimally-invasive surgery in the stages of non–small cell lung cancers (NSCLC).

Benny Weksler, MD, FACS, chief, Division of Thoracic Surgery, professor, Surgery, University of Tennessee Health Science Center, Eastridge-Cole Endowed Professor of Thoracic Surgery, West Cancer Center, discusses the role of minimally invasive surgery in the stages of non—small cell lung cancer (NSCLC).

Neoadjuvant therapy for stage I and stage II lung cancers have been shown to be ineffective for the treatment of these patients. Neoadjuvant therapy was the initial approach in stage III cancers, prior to surgery. However, after clinical trials showed that chemotherapy, radiation, and surgery showed the same result, a lot of practitioners ended up doing definitive chemotherapy and radiation, says Weksler. Surgery was reserved for select few patients.

Adjuvant therapy may be more beneficial for patients with stage II disease with tumors that are larger than 4 centimeters in diameter. Those patients are surviving longer with an adjuvant approach.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD